


<b>FORM PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office	Docket No.: UCSD1630-1	Application No.: 09/991,518
	Applicants: Fenical, et al.	Confirmation No.: 7755
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Filing Date: November 16, 2001	Group Art Unit: 1651



### U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
m	A	2001/002391	5/31/01	Brandt, et al.			
	B	2001/051654	12/13/01	Elliott, et al.			
J	C	2004/0138196	7/15/04	Fenical, et al.	514	192	

### FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
m	D	WO96/32105	10/17/96	PCT			
	E	WO00/23614	4/27/00	PCT			
	F	WO/02/47610	6/20/02	PCT			
	G	WO/2004/071382	8/26/04	PCT			
J	H	WO/2005003137	1/31/05	PCT			

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

m	I	Beers, et al., "The Merck Manual of Diagnosis & Therapy" Seventeenth Edition, Merck Research Lab. Pages 1157, col. 2, page 1158 col. 2, page 1241, col. 2, page 1252, col. 1, Whitehouse Station NJ (1999)
	J	Crane, et al., "A Novel Enantioselective Synthetic Route to Omuralide Analogues with te Potential for Species Selectivity in Proteasome Inhibition", Organic Letters 3(9):1395-1397 (2001)
	K	DeLong, et. al., "Environmental Diversity of Bacteria and Archaea", Syst. Biol. 50(4):470-478, (2001)
	L	Elliott, et al., "The proteasome: A new Target for Novel Drug Therapies", Am. J. of Clin Pathology. 116(5):637-646 (2001).
J	M	Feling, et al., "Salinospormide A: A Highly Cytotoxic Proteasome Inhibitor from a Novel Microbial Source, A Marine Bacterium of the New Genus Salinospora" Angewandte Chemie (Intl. ed. In English) 2003

pages 355 - 357

<b>EXAMINER</b> GTV6442311.1 328342-202 <i>Jane Marx</i>	<b>DATE CONSIDERED</b> 6/20/05
---	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>FORM PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office	Docket No.: UCSD1630-1	Application No.: 09/991,518
	Applicants: Fenical, et al.	Confirmation No.: 7755
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Filing Date: November 16, 2001	Group Art Unit: 1651

2a	N	Fenical, et al., "Marine Microorganisms as a Developing Resource for Drug Discovery", <i>Pharmaceutical News</i> , 9/6, 489-494 (2002).
	O	Gantt, et al., "proteasome Inhibitors Block Development of Plasmodium Spp", <i>Antimicrobial Agents and Chemotherapy</i> 42(10):2731-2738 (1998).
	P	Giovannoni, Steven, "Oceans of Bacteria", <i>Nature</i> 430:515-516, (July 29, 2004).
	Q	Goldberg, et al., "Not Just Research Tools-proteasome Inhibitors Offer Therapeutic Promise", <i>Nature Medicine</i> , 8(4):338-340 (2002).
	R	Newton, "Il Fondo Agli Oceani Potenti Antibiotici e Anticancro" XP002304843 Abstract-English
	S	Nicholas, B.J.R., "Symbiotic Approach to Drug Design" <i>Decision in Drug Design</i> , 173-186 (1983).
	T	Rajender, et al., "A Simple Stereocontrolled Synthesis of Salinospramide A" <i>J. Am. Chem Soc.</i> 126(20):6230 (April 2004).
	U	Rappe, et al., "Cultivation of the Ubiquitous SAR11 Marine Bacterioplankton Clade," <i>Nature</i> 418:630-633, (August 8, 2002).
	V	Stackebrandt, et al., "Proposal for a New Hierarchic Classification System," <i>Intl. J. of Systematic Bacteriology</i> 47(2):479-490 (1997).
	W	Tang, et al., "Proteasome Activity is Required for Anthrax Lethal Toxin to Kill Macrophages", <i>Infection &amp; Immunity</i> 67(6):3055-3060 (June 1999)
	X	Ward, Bess, "How Many Species of Prokaryotes Are There?" <i>PNAS</i> 99(16):10234-10236 (August 6, 2002).
	Y	Wheelis, et al., "On the Nature of Global Classification", <i>PNAS</i> 89:2930-2934, (April 1992).
	Z	Woese, Carl, "Bacterial Evolution", <i>Microbiological Rev.</i> 51(2):221-271 (June 1987)

<b>EXAMINER</b> GT6442311.1 328342-202	<b>DATE CONSIDERED</b> 6/20/05
--	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.